MGMT and central nervous system cancer: In our series, glioma patients with methylated MGMT sequences were seen as strong prognostic factor in terms of better OS and PFS of 40 and 23.9 months versus 6.7 and 3.3 months in unmethylated MGMT respectively (p = 0.000) which is in accordance with previous reports46,47.